



an Open Access Journal by MDPI

## New Advances in Tumor Metastasis Angiogenesis-Dependent Processes

Guest Editors:

### Dr. Jimmy Stalin

Pathology, Department of Oncology, Microbiology and Immunology, Section of Medicine, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, CH-1700 Fribourg, Switzerland

### Prof. Dr. Curzio R. Rüegg

Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland

Deadline for manuscript submissions:

**closed (15 September 2023)**

### Message from the Guest Editors

In 2022, the World Health Organization estimates that cancer is the leading cause of death worldwide. The spreading of tumor cells from the primary tumor to surrounding tissues and distant organs, also called metastasis, constitutes the main cause of cancer-associated morbidity and mortality worldwide. It occurs in a wide range of solid tumors including breast, colorectal, liver, skin cancers, and others. It has been estimated that 90% of cancer deaths are due to metastasis. The cellular and molecular mechanisms behind the angiogenic role in metastatic spreading are still under investigation. Defining them is crucial to highlight novel potential therapeutic opportunities and combinations and overcome therapeutic resistance altogether to increase patient survival.

This Special Issue will cover the following topics:

- Angiogenic cellular and molecular mechanisms regulating metastatic spreading and metastasis growth.
- Anti-angiogenic therapies for metastatic spreading and metastasis growth targeting.

Review, research articles, and clinical evaluations are welcome.



[mdpi.com/si/139328](https://mdpi.com/si/139328)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)